
Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf-" ;
-# - ;
- $ |
( & , &); |
|
- , % ; |
||
-" " # , % & & 1-3 ; |
||
? : |
|
|
- |
, 3 |
" " ; |
- 5-8 |
|
|
- # - - |
; |
- % & % & – & , &-& ;
-" ;
-" 3 " , .
- - V$& - " # , -
- % & ( & ), " , % " ; - " " # % , % & 7-10- &
- |
'B; , |
3 |
" " ; |
-% & & 3-6 ;
-& ;
-, " , %
, |
& |
, |
% |
|
; |
|
|
|
|
- |
&, " , |
, " |
; |
|
- % |
& " |
|
- " % -& ;:
- ;
-1-3 ;
-& - -;
-" , ;
-"
-,;
- # - & , & G : & , , % & , " & , &.
' " "$: , &; " ; " & % , – &, &. ' ""$ , – .
" & :
1.! ( 3 , & .)
2.V ( )
" & & :
+ :
J " & % " . < & $ . H %$# % & &.
+ " $"$ & ": , " % # ,, & " & – " , "
5.Principles of Appropriate Antibiotic Use for Treatment of Nonspecific Upper Respiratory Tract Infections in Adults: Background. Ann Intern Med. 2001;134:490. Ralph Gonzales, John G. Bartlett, Richard E. Besser et al.
6.Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis. Rhinology. 2004 Dec;42(4):207. Lund VJ, Grouin JM, Eccles R et al.
7.! " & – – @ , 2000 .
* – , # (% % ) ** - " & , "$ &
" % &
: 05-052
"$ &: ": 6! ( )
& ! :
1. & % & &(?@), % $# , & " ; 2. % & " & ;
3. % & $ % - . + ?@ ( % ?@), " , % , ,.
4. ?@.
' & & : 8-10 ( % # " )(: I10 7 & ( " ) .
) : & - & !?@ 140 . . . / @?@ 90 . . . ( & ," . < & 3 % & $# , %$# ?@.
?@ 2 :
7 &$ "$ "$.
$ :
7 & :& ?@:
1.& ?@ < 120 / 80 . . .
2.+ & ?@ <130 / 85 . . .
3. ' & ?@ 130 - 139 / 85-89 . . . ! ? :
1.! &1 140-159 / 90-99
2.! & 2 160-179/100-109
3.! & 3 Š180 / Š110
4.B " Š140/ <90" :
1.@ " " " ;
2. ) " " " # " ? .
3. " ? - V ?@. ! " :
1. " "
2.7 3. , %
4./ ( % )
* :
# "- ( % # 65%" 55 ), , & % ,& % , # , , % " &, ,
, |
|
% , |
|
& |
+ '!, . " . |
|
|||
|
|
: " ?@ |
|
140 . . . / |
" ?@ - 90 . . . ( & ," ), & 3 % & J!, $# , %$# ?@. @ & , $# " ? % .
@ " $# :
1.& " .
2. |
B & V ?@ (> 180/120 . .). |
3. |
+ " V V & , & |
. |
|
" & : |
|
1 |
! ( .) |
2 |
V ( , ?@, & .) |
" & & :
+ : + . + &% ( & &, " & , & & "$ &), $ " ( & 5-6 ).
6 :
1.@ : 12, 5- 25 , 1, 5 – 2,5 / .
2.†-: 25-100 1-2 , 25 -100 / .
3.B ?_: 3 10-20 / .
4.? & : 5-10 / , - 30-60 / .
5.œ-: 1-8 / .
; " |
% – $ " 3-6 " . |
% ?@ |
#&$ . |
•+ – 10-20 &, % & (
" % )
• 7 – 1,25 \ , " 3 .
" & :
1.* 25
2. **B 2,5
4.< 50 , 100
5.**7 , 2,5 , 10 ; 1,25 /1
6.**? , 5 , 10
7.*+ 10 , 20 ,
8.*@ 1 ,
9.*+ 50 /
10.**? , 50 , 100
" & & :,- ! : % " .
/ , & :
1." . _" " . « 7 ;?-6>@», 2004.
2.;h 2003 Canadian Recommendations for the Management of Hypertension. Canadian Hypertension Education Program.www.hypertension.car\recommendations 2003 va.html
3." , "$ "
& " . ; , 2005
4.! " & . @ ,2000
* – |
, # |
(% % ) |
|
** |
- " & |
|
, " |
$ |
& |
" . ) .
: 04–140
"$ &: ": 6! ( ) / & 3 :
1.' # 2. 3. # % .
' & & : 1 &
(: R55 [ ]
) : – , #.
$ :
1.+ "- :
-' ( & )
-!
-+ "
-J
-"
2.! " –
-! % "
-?
3.+ % .
* : & , , & V $#, % " , ,, & " 3 , " , & 3 .
: , « » & , & % , S , AD % , .
H : %$# ( % , ,, ).
" & :
1.! - $# , .
2. V - & ( , |
& , |
|
, , .) |
|
|
" & & |
: |
|
+ : + % & |
& |
& , |
& $ & $# % . ! & &
$& #$ % &. |
|
||
|
,- ! : |
||
3 " |
& " " |
||
" . H 5 |
– " . |
||
/ , |
& : |
||
1.! " |
" " . 6 2001 . |
||
2.; , .<.; 6 1999 . |
|||
3.! " & - -@ 2001 . |
|||
* – |
, # (% % ) |
9
: 23-317
"$ &: ": 6! ( )
& ! : !@ !@, " " " , & " " ,, - & % ,.
' & & : %(:
>10 B
>11 B
>12 ! , " &$
>13 @ "
>14 ! "
) : 9 (!@) – 3 " ( ) , $# " , & , 3 .
$ : : !@ 1 !@ 2 .
!@ 1 (!@ 1) – 3 " , $, # $ , . !@ 1 $#% " % , & " #
. 3 |
& !@ |
1 % |
" & |
. |
+ " V |
|
|||
. ) " # 30 ( 20-25% " ). |
||||
!@ 2 (!@ 2) " $ 35-40 , |
|
|||
" |
. !@ |
2 90% " !@. 3 |
. @ 3"$ %$# , " %
& " . |
|
* : |
|
_ !@ 1: # & |
!@ 1, |
( , . .) |
|
_ !@ 2: # & |
!@ 2; % ; & |
; !@ ; , 4,0 ; % # , 4,0 ; % # % .
|
: |
|
|
!@ 1 " " : % % , |
, % , |
||
& . . 7 |
, .". . |
||
' |
" |
1 , !@ 2 , , |
" &, |
& " . ! " " " & % : &, , %, . !@ 2 " # " % $ .